Portuguese recommendations for the management of transthyretin amyloid cardiomyopathy (Part 1 of 2): Screening, diagnosis and treatment. Developed by the Task Force on the management of transthyretin amyloid cardiomyopathy of the Working Group on Myocardial and Pericardial Diseases of the Portuguese Society of Cardiology
Nuno Marques(Hospital do Espírito Santo), Olga Azevedo(British Heart Foundation), Luís R. Lopes(Barts Health NHS Trust), Nuno Cardim, Dulce Brito(University of Lisbon), R Fernandes(Algarve Biomedical Center), Dina Bento(Algarve Biomedical Center), Catarina Ferreira(University of Trás-os-Montes and Alto Douro), Sílvia Aguiar Rosa(Administração Regional de Saúde de Lisboa e Vale do Tejo)
Cited by 3
Related Papers
2023 ESC Guidelines for the management of cardiomyopathies
|European Heart Journal|2023|2.3k
Current and Evolving Echocardiographic Techniques for the Quantitative Evaluation of Cardiac Mechanics: ASE/EAE Consensus Statement on Methodology and Indications
|Journal of the American Society of Echocardiography|2011|1.2k
Current and Evolving Echocardiographic Techniques for the Quantitative Evaluation of Cardiac Mechanics: ASE/EAE Consensus Statement on Methodology and Indications Endorsed by the Japanese Society of Echocardiography
|European Journal of Echocardiography|2011|1.1k
Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
|New England Journal of Medicine|2024|410
Echocardiographic reference ranges for normal left ventricular 2D strain: results from the EACVI NORRE study
|European Heart Journal - Cardiovascular Imaging|2017|348